Meinuohua: The company's stock price has experienced a significant short-term increase, indicating a clear bubble.

Announcement of abnormal fluctuations in Minoahua stock trading: The company's stock price has experienced a large short-term increase, with risks of market sentiment overheating, irrational speculation, and noticeable bubble formation. There is a potential risk of rapid decline at any time. The company has noticed discussions in the market and some channels regarding the company's related research data, progress in clinical trials, and future development plans. JH389 is a probiotic product, not a drug, and has many limitations as a dietary supplement. The company's in-development product JH389 is a probiotic and is planned to be marketed as a dietary supplement in the future, but is currently in the research trial stage. Previous trial data has limitations. The sample size for the JH389 probiotic product in domestic trials was 28 cases, in a small-scale 8-week trial, and due to the relatively limited sample size, the generalizability of the conclusions needs further verification in a larger population. The certainty of the conclusions is not yet sufficient.